Anton Belousov

2.4k total citations
38 papers, 1.0k citations indexed

About

Anton Belousov is a scholar working on Oncology, Pathology and Forensic Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Anton Belousov has authored 38 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 13 papers in Pathology and Forensic Medicine and 10 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Anton Belousov's work include CAR-T cell therapy research (14 papers), Lymphoma Diagnosis and Treatment (11 papers) and Monoclonal and Polyclonal Antibodies Research (9 papers). Anton Belousov is often cited by papers focused on CAR-T cell therapy research (14 papers), Lymphoma Diagnosis and Treatment (11 papers) and Monoclonal and Polyclonal Antibodies Research (9 papers). Anton Belousov collaborates with scholars based in Switzerland, United States and United Kingdom. Anton Belousov's co-authors include Pablo Umaña, Marina Bacac, Victor Levitsky, Petra Herzig, Christian Klein, Philipp Müller, Andreas Roller, Wolfgang Moersig, Alfred Zippelius and Daniela S. Thommen and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Anton Belousov

32 papers receiving 999 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anton Belousov Switzerland	14	661	308	275	214	156	38	1.0k
Micaela Hernberg Finland	20	680 1.0×	419 1.4×	148 0.5×	408 1.9×	89 0.6×	58	1.1k
Matthew A. Smith United States	19	350 0.5×	247 0.8×	243 0.9×	390 1.8×	39 0.3×	38	1.1k
Werner Wackernagel Austria	13	516 0.8×	233 0.8×	115 0.4×	653 3.1×	264 1.7×	38	1.4k
Jingwei Sun China	11	717 1.1×	753 2.4×	193 0.7×	438 2.0×	69 0.4×	22	1.3k
Marzia Locatelli Italy	17	757 1.1×	151 0.5×	221 0.8×	329 1.5×	135 0.9×	36	1.2k
David J. Byrne Australia	20	627 0.9×	233 0.8×	295 1.1×	333 1.6×	78 0.5×	51	1.2k
Ana Carneiro Sweden	16	650 1.0×	272 0.9×	203 0.7×	467 2.2×	36 0.2×	46	1.1k
Veronique Neumeister United States	17	496 0.8×	92 0.3×	170 0.6×	510 2.4×	104 0.7×	35	968
Hojabr Kakavand Australia	15	1.1k 1.7×	583 1.9×	179 0.7×	501 2.3×	67 0.4×	20	1.4k
A Houghton United States	9	632 1.0×	386 1.3×	65 0.2×	534 2.5×	127 0.8×	11	1.1k

Countries citing papers authored by Anton Belousov

Since Specialization

Citations

This map shows the geographic impact of Anton Belousov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anton Belousov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anton Belousov more than expected).

Fields of papers citing papers by Anton Belousov

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anton Belousov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anton Belousov. The network helps show where Anton Belousov may publish in the future.

Co-authorship network of co-authors of Anton Belousov

This figure shows the co-authorship network connecting the top 25 collaborators of Anton Belousov. A scholar is included among the top collaborators of Anton Belousov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anton Belousov. Anton Belousov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Abramson, Jeremy S., Matthew Ku, Mark Hertzberg, et al.. (2025). Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year (yr) follow-up of STARGLO.. Journal of Clinical Oncology. 43(16_suppl). 7015–7015.

Bender, Brendan C., et al.. (2024). Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies. Clinical Cancer Research. 31(2). 245–257. 11 indexed citations

Bender, Brendan C., et al.. (2024). Cytokine Release Syndrome: Trends with T Cell Engaging Bispecifics from a Systematic Review of Licensing Applications. Blood. 144(Supplement 1). 5798–5798. 1 indexed citations

Carlo‐Stella, Carmelo, Cyrus Khan, Martin Hutchings, et al.. (2021). ABCL-360: Glofitamab Step-Up Dosing (SUD): Updated Efficacy Data Show High Complete Response Rates in Heavily Pretreated Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (Pts). Clinical Lymphoma Myeloma & Leukemia. 21. S394–S394. 2 indexed citations

Carlo‐Stella, Carmelo, Cyrus Khan, Martin Hutchings, et al.. (2021). Oral Abstract: ABCL-360: Glofitamab Step-Up Dosing (SUD): Updated Efficacy Data Show High Complete Response Rates in Heavily Pretreated Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (Pts). Clinical Lymphoma Myeloma & Leukemia. 21. S203–S203.

Chen, Gong, Ya‐Chi Chen, Bernhard Reis, et al.. (2018). Combining expression of GPC3 in tumors and CD16 on NK cells from peripheral blood to identify patients responding to codrituzumab. Oncotarget. 9(12). 10436–10444. 13 indexed citations

Nguyen, Frédérique, L. Peña, Catherine Ibisch, et al.. (2017). Canine invasive mammary carcinomas as models of human breast cancer. Part 1: natural history and prognostic factors. Breast Cancer Research and Treatment. 167(3). 635–648. 99 indexed citations

Abadie, Jérôme, Frédérique Nguyen, Delphine Loussouarn, et al.. (2017). Canine invasive mammary carcinomas as models of human breast cancer. Part 2: immunophenotypes and prognostic significance. Breast Cancer Research and Treatment. 167(2). 459–468. 84 indexed citations

Melero, Ignacio, Neil H. Segal, Willeke Ros, et al.. (2017). Pharmacokinetics (PK) and pharmacodynamics (PD) of a novel carcinoembryonic antigen (CEA) T-cell bispecific antibody (CEA CD3 TCB) for the treatment of CEA-expressing solid tumors.. Journal of Clinical Oncology. 35(15_suppl). 2549–2549. 1 indexed citations

10.

Boult, Jessica K.R., Markus Thomas, Astrid Koehler, et al.. (2016). Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling. British Journal of Cancer. 115(6). 691–702. 14 indexed citations

11.

Thommen, Daniela S., Jens Schreiner, Philipp Müller, et al.. (2015). Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors. Cancer Immunology Research. 3(12). 1344–1355. 315 indexed citations

12.

Morrow, Jarrett D., Weiliang Qiu, Divya Chhabra, et al.. (2015). Identifying a gene expression signature of frequent COPD exacerbations in peripheral blood using network methods. BMC Medical Genomics. 8(1). 1–1. 50 indexed citations

13.

Schreiner, Jens, Daniela S. Thommen, Petra Herzig, et al.. (2015). Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor. OncoImmunology. 5(2). e1062969–e1062969. 28 indexed citations

14.

Oppenheim, David, Roberto Spreafico, Annie Etuk, et al.. (2014). Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy. British Journal of Cancer. 110(5). 1221–1227. 22 indexed citations

15.

Prat, Aleix, Giampaolo Bianchini, Marlène Thomas, et al.. (2014). Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study. Clinical Cancer Research. 20(2). 511–521. 158 indexed citations

16.

Thomas, Marlène, et al.. (2013). An optimized workflow for improved gene expression profiling for formalin-fixed, paraffin-embedded tumor samples. PubMed. 3(1). 10–10. 13 indexed citations

17.

Herold, Andrea, Tobias Bergauer, Anton Belousov, et al.. (2012). Gene expression analysis in biomarker research and early drug development using function tested reverse transcription quantitative real-time PCR assays. Methods. 59(1). 10–19. 14 indexed citations

18.

Michaelis, Elias K., Xinkun Wang, Ranu Pal, et al.. (2011). Neuronal Glud1 (glutamate dehydrogenase 1) over-expressing mice: Increased glutamate formation and synaptic release, loss of synaptic activity, and adaptive changes in genomic expression. Neurochemistry International. 59(4). 473–481. 31 indexed citations

19.

Nguyen, Frédérique, Jérôme Abadie, Delphine Loussouarn, et al.. (2011). PD08-10: High Frequency of Triple Negative Mammary Carcinomas in the Dog as Model of Human Breast Cancer.. Cancer Research. 71(24_Supplement). PD08–10.

20.

Bianchini, Giampaolo, Aleix Prat, Marlene Pickl, et al.. (2011). Response to neoadjuvant trastuzumab and chemotherapy in ER+ and ER- HER2-positive breast cancers: Gene expression analysis.. Journal of Clinical Oncology. 29(15_suppl). 529–529. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact